Cempra to Report Fourth Quarter and Full Year 2015 Financial Results
17 févr. 2016 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics in the face of rising antibiotic...
The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra’s Oral Solithromycin in Community-Acquired Bacterial Pneumonia
05 févr. 2016 07h00 HE
|
Melinta Therapeutics, Inc.
Solithromycin met primary and secondary objectives of non-inferiority compared to moxifloxacin, a potent fluoroquinolone Cempra plans to complete a New Drug Application (NDA) submission to the FDA...
Cempra to Present at the Leerink Partners 5th Annual Global Healthcare Conference
03 févr. 2016 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra and Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement for Solithromycin
01 févr. 2016 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C. and WATERTOWN, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (NASDAQ:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical...
Cempra to Ring NASDAQ Closing Bell to Mark 10th Anniversary
26 janv. 2016 08h00 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Completes Public Offering of Common Stock
12 janv. 2016 16h05 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Prices Public Offering of Common Stock
06 janv. 2016 20h42 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present at J.P. Morgan Healthcare Conference
06 janv. 2016 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces Proposed Public Offering of $175 Million of Common Stock
05 janv. 2016 16h10 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Doses Initial Patient in Phase 2 Clinical Trial of Solithromycin in NASH
05 janv. 2016 07h00 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...